The favorable prognosis included patients with high tumor stage, which echoes prior studies demonstrating a favorable outcome of uterine tumors with POLE exonuclease mutations despite adverse standard clinicopathologic indicators including high grade, high stage, and lymphovascular invasion [3, 45]. The gene discussed is POLE; the disease is neoplasm.